Ligand Pharmaceuticals reported $828.53M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
Amgen USD 7.43B 1.22B Jun/2025
Arrowhead Research USD 522.31M 161.91M Jun/2025
Baxter International USD 7.05B 90M Mar/2025
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
Gilead Sciences USD 19.67B 596M Jun/2025
GlaxoSmithKline GBP 14.35B 197M Jun/2025
Glaxosmithkline GBP 14.35B 683M Jun/2025
Insmed USD 1.25B 1.15B Jun/2025
Ionis Pharmaceuticals USD 631.72M 156M Jun/2025
Ligand Pharmaceuticals USD 828.53M 32.99M Jun/2025
MacroGenics USD 46.62M 69.44M Jun/2025
Merck USD 49.06B 725M Jun/2025
Pacira USD 757.77M 40.77M Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
Veracyte USD 1.22B 26.12M Jun/2025